載入中
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
一般交易時段
US$11.215
−US$0.475 · -4.06%
盤中時間採用ET。市場資料可能有所延遲。
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
日內區間
目前US$11.215
52週區間
目前US$11.215
盤中時間採用ET。市場資料可能有所延遲。
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
日內區間
目前US$11.215
52週區間
目前US$11.215
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.18億 USD | 1.19億 USD | 8751.8萬 USD | 6505.3萬 USD | 4402.7萬 USD |
| 銷售、一般及管理費用 | 6060.1萬 USD | 5916.6萬 USD | 4940.1萬 USD | 4535萬 USD | 3919.4萬 USD |
| 營業費用 | 1.79億 USD | 1.78億 USD | 1.37億 USD | 1.1億 USD | 8322.1萬 USD |
| 利息收入 | 718.2萬 USD | 826.8萬 USD | 462.3萬 USD | — | — |
| 利息支出 | 451.7萬 USD | 447.9萬 USD | 220.4萬 USD | — | — |
| 折舊和攤銷 | 21.6萬 USD | 23.3萬 USD | 24.2萬 USD | 33萬 USD | 17.5萬 USD |
| 營業利益 | −1.79億 USD | −1.78億 USD | −1.37億 USD | −1.1億 USD | −8322.1萬 USD |
| 淨利 | −2.88億 USD | −1.55億 USD | −1.18億 USD | −9150.5萬 USD | −7174.2萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$18.63
上漲空間 66.12%報告持有此股票曝險的交易所交易基金。
ARK Genomic Revolution ETFARKG5457.5萬2.59%15.57億 USD0.75%US$48.68-2.91%
iShares Biotechnology ETFIBB1005.11萬0.10%104.01億 USD0.44%US$197.58-2.84%
AdvisorShares Psychedelics ETFPSIL550.92萬11.42%4822.45萬 USD1.84%US$20.65-2.41%
ALPS Medical Breakthroughs ETFSBIO205.59萬1.09%1.88億 USD0.50%US$52.88-2.31%
State Street SPDR S&P International Small Cap ETFGWX115.81萬0.13%9.26億 USD0.40%US$45.025-1.00%
Simplify Propel Opportunities ETFSURI105.66萬1.41%7484.06萬 USD2.82%US$16.92+0.42%
ROBO Global Healthcare Technology and Innovation ETFHTEC89.59萬0.95%1.03億 USD0.80%US$41.78-1.86%
AdvisorShares Dorsey WrightAADR68.52萬1.84%3727.04萬 USD1.17%US$79.98-1.27%ARK Genomic Revolution ETFARKGiShares Biotechnology ETFIBBAdvisorShares Psychedelics ETFPSILALPS Medical Breakthroughs ETFSBIOState Street SPDR S&P International Small Cap ETFGWXSimplify Propel Opportunities ETFSURIROBO Global Healthcare Technology and Innovation ETFHTECAdvisorShares Dorsey WrightAADRAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
